358 related articles for article (PubMed ID: 8720317)
1. In vitro activity of a new rifamycin derivative against Mycobacterium leprae.
Dhople AM; Dimova V
Arzneimittelforschung; 1996 Feb; 46(2):210-2. PubMed ID: 8720317
[TBL] [Abstract][Full Text] [Related]
2. In vitro synergistic activity between ofloxacin and ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA; Gardner GD
Arzneimittelforschung; 1993 Mar; 43(3):384-6. PubMed ID: 8387790
[TBL] [Abstract][Full Text] [Related]
3. Comparative in vitro activities of rifamycin analogues against Mycobacterium leprae.
Dhople AM
Indian J Lepr; 1997; 69(4):377-84. PubMed ID: 9474513
[TBL] [Abstract][Full Text] [Related]
4. In-vitro activity of sitafloxacin (DU-6859a), either singly or in combination with rifampin analogs, against Mycobacterium leprae.
Dhople AM; Namba K
J Infect Chemother; 2003 Mar; 9(1):12-5. PubMed ID: 12673400
[TBL] [Abstract][Full Text] [Related]
5. The in-vitro activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1995 Apr; 35(4):463-71. PubMed ID: 7628981
[TBL] [Abstract][Full Text] [Related]
6. In vitro and in vivo interactions of drugs used in multidrug therapy in leprosy.
Dhople AM; Lamoureux LC; Gardner GD
Indian J Lepr; 1991; 63(2):166-79. PubMed ID: 1664440
[TBL] [Abstract][Full Text] [Related]
7. The activity of rifabutin against Mycobacterium leprae.
Yoder LJ; Jacobson RR; Hastings RC
Lepr Rev; 1991 Sep; 62(3):280-7. PubMed ID: 1665534
[TBL] [Abstract][Full Text] [Related]
8. In vivo susceptibility of Mycobacterium leprae to ofloxacin either singly or in combination with rifampicin and rifabutin. Anti-leprosy activity of ofloxacin and ansamycins in mice.
Dhople AM; Ibanez MA
Arzneimittelforschung; 1994 Apr; 44(4):563-5. PubMed ID: 8011013
[TBL] [Abstract][Full Text] [Related]
9. In vitro activity of levofloxacin, singly and in combination with rifamycin analogs, against Mycobacterium leprae.
Dhople AM; Ibanez MA
Antimicrob Agents Chemother; 1995 Sep; 39(9):2116-9. PubMed ID: 8540726
[TBL] [Abstract][Full Text] [Related]
10. In vitro and in vivo effects of N-methyl-3,5-dichloro-benzylamine hydrochloride on Mycobacterium leprae.
Dhople AM; Strong LC; Meindl W; Schoenenberger H; Gardner GD
Arzneimittelforschung; 1991 Mar; 41(3):253-6. PubMed ID: 1867663
[TBL] [Abstract][Full Text] [Related]
11. A Mycobacterium leprae isolate resistant to dapsone, rifampin, ofloxacin and sparfloxacin.
Matsuoka M; Kashiwabara Y; Namisato M
Int J Lepr Other Mycobact Dis; 2000 Dec; 68(4):452-5. PubMed ID: 11332288
[TBL] [Abstract][Full Text] [Related]
12. In-vitro activity of three new fluoroquinolones and synergy with ansamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
J Antimicrob Chemother; 1993 Sep; 32(3):445-51. PubMed ID: 8262866
[TBL] [Abstract][Full Text] [Related]
13. In vivo activities of novel benzoxazinorifamycins against Mycobacterium leprae.
Dhople AM; Ibanez MA
Indian J Lepr; 1995; 67(4):375-82. PubMed ID: 8849914
[TBL] [Abstract][Full Text] [Related]
14. The activity of rifabutin against Mycobacterium leprae in armadillos.
Dhople AM; Williams SL
Int J Antimicrob Agents; 1997 Jan; 9(3):169-73. PubMed ID: 9552713
[TBL] [Abstract][Full Text] [Related]
15. Multivariate analysis of the activity of rifamycins against rapidly growing Mycobacteria, to define an in vitro screening model for their activity against mycobacterium leprae.
Pattyn SR; Hébrant F
Arzneimittelforschung; 1980; 30(12):2099-103. PubMed ID: 7011330
[TBL] [Abstract][Full Text] [Related]
16. Multidrug-resistance to dapsone, rifampicin, and ofloxacin in Mycobacterium leprae.
Cambau E; Perani E; Guillemin I; Jamet P; Ji B
Lancet; 1997 Jan; 349(9045):103-4. PubMed ID: 8996430
[No Abstract] [Full Text] [Related]
17. Antimycobacterial activities of two newer ansamycins, R-76-1 and DL 473.
Ji BH; Chen JK; Lu XZ; Wang SY; Ni GX; Hou YH; Zhou DH; Tang QK
Int J Lepr Other Mycobact Dis; 1986 Dec; 54(4):563-77. PubMed ID: 3546547
[TBL] [Abstract][Full Text] [Related]
18. Multidrug resistant Mycobacterium leprae from patients with leprosy.
Maeda S; Matsuoka M; Nakata N; Kai M; Maeda Y; Hashimoto K; Kimura H; Kobayashi K; Kashiwabara Y
Antimicrob Agents Chemother; 2001 Dec; 45(12):3635-9. PubMed ID: 11709358
[TBL] [Abstract][Full Text] [Related]
19. In vivo susceptibility of Mycobacterium leprae to sitafloxacin (DU-6859a), either singly or in combination with rifampicin analogues.
Dhople AM; Namba K
Int J Antimicrob Agents; 2003 Mar; 21(3):251-5. PubMed ID: 12636987
[TBL] [Abstract][Full Text] [Related]
20. In vitro and in vivo activity of K-130, a dihydrofolate reductase inhibitor, against Mycobacterium leprae.
Dhople AM
Arzneimittelforschung; 1999 Mar; 49(3):267-71. PubMed ID: 10219472
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]